Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
21 July 2016
Deals | France | Capital Markets
Gide advised GenSight Biologics, a biotechnology company, on its initial public offering (IPO) on the regulated market of Euronext Paris. The initial public offering raised approximately €45.9 million of capital through the issuance of new shares in an amount of €40 million with an over-allotment option to issue additional new shares in an amount of approximately €5.9 million. Based on the offering price of €8.00 per share, the company’s market capitalization is expected to amount to approximately €154.8 million, assuming the exercise of the over-allotment option.
GenSight Biologics is a biotechnology company discovering and developing innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
Settlement-delivery of the newly issued shares occurred on July 14, 2016.
GenSight Biologics' initial public offering has been the largest public fundraising this year by a French biotechnology company.
The Gide team was led by Melinda Arsouze and Karen Noël (partners), and comprised Théophile Strebelle, Scott Logan and Guillaume Leteurtrois (associates).
